OBJECTIVE: The clinical efficacy and tolerability of denosumab in severe osteoporosis are well-known. However, the evaluation on general health and quality of life over time and compared to population norms is still lacking. We aimed at evaluating denosumab effectiveness in a real-world clinical sample with a 6-years average follow-up. PATIENTS AND METHODS: In this retrospective-matched study with prospective data collection, a total of 101 patients affected by severe osteoporosis and treated with denosumab between 2014 and 2020 were evaluated. All patients completed the self- perceived quality of life (36-Item Short Form - SF-36) survey and visual analogue scale (VAS) before and after treatment. RESULTS: Overall, 13 patients died of causes unrelated to the procedure, 12 stopped therapy with denosumab, and 30 did not participate in the follow-up; thus, 46 patients completed the study. There were 44 (95.7%) women and 93.4% of patients reported history of osteoporotic fractures. The mean follow-up was 59 +/- 17.8 months and the mean age at follow-up was 73.9 +/- 10.6 years. We found a significant improvement in bodily pain (baseline 53.8 +/- 33.4, follow-up 62.7 +/- 26.6; p=0.002) and in general health (baseline 35 +/- 25.4, follow-up 41.7 +/- 24.2; p= 0.002) over time. The bodily pain score at follow-up was similar to the mean of the age- matched healthy population (62.7 +/- 26.6 vs. 67.6 +/- 26, p= 0.374). The MCS-36 scores were higher than the normative values before treatment and at follow-up (51.6 +/- 9.8 vs. 45.8 +/- 9, p= 0.004 and 50.6 +/- 11.7 vs. 45.8 +/- 9, p= 0.030, respectively). The PCS-36 score at follow-up was comparable to the normative values (39.4 +/- 10.4 vs. 42.7 +/- 9, p= 0.107). CONCLUSIONS: Denosumab is effective to improve bone health and global mental and physical wellbeing, and quality of life over time.

Improvement in health status and quality of life in patients with osteoporosis treated with denosumab: results at a mean follow-up of six years

Mercurio, M;Familiari, F;de Filippis, R;Napoleone, F;Galasso, O;Gasparini, G
2022-01-01

Abstract

OBJECTIVE: The clinical efficacy and tolerability of denosumab in severe osteoporosis are well-known. However, the evaluation on general health and quality of life over time and compared to population norms is still lacking. We aimed at evaluating denosumab effectiveness in a real-world clinical sample with a 6-years average follow-up. PATIENTS AND METHODS: In this retrospective-matched study with prospective data collection, a total of 101 patients affected by severe osteoporosis and treated with denosumab between 2014 and 2020 were evaluated. All patients completed the self- perceived quality of life (36-Item Short Form - SF-36) survey and visual analogue scale (VAS) before and after treatment. RESULTS: Overall, 13 patients died of causes unrelated to the procedure, 12 stopped therapy with denosumab, and 30 did not participate in the follow-up; thus, 46 patients completed the study. There were 44 (95.7%) women and 93.4% of patients reported history of osteoporotic fractures. The mean follow-up was 59 +/- 17.8 months and the mean age at follow-up was 73.9 +/- 10.6 years. We found a significant improvement in bodily pain (baseline 53.8 +/- 33.4, follow-up 62.7 +/- 26.6; p=0.002) and in general health (baseline 35 +/- 25.4, follow-up 41.7 +/- 24.2; p= 0.002) over time. The bodily pain score at follow-up was similar to the mean of the age- matched healthy population (62.7 +/- 26.6 vs. 67.6 +/- 26, p= 0.374). The MCS-36 scores were higher than the normative values before treatment and at follow-up (51.6 +/- 9.8 vs. 45.8 +/- 9, p= 0.004 and 50.6 +/- 11.7 vs. 45.8 +/- 9, p= 0.030, respectively). The PCS-36 score at follow-up was comparable to the normative values (39.4 +/- 10.4 vs. 42.7 +/- 9, p= 0.107). CONCLUSIONS: Denosumab is effective to improve bone health and global mental and physical wellbeing, and quality of life over time.
2022
Chronic disease
Denosumab
Mental health
Osteoporosis
Quality of life
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12317/84983
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact